Edition:
United Kingdom

ProQR Therapeutics NV (PRQR.OQ)

PRQR.OQ on NASDAQ Stock Exchange Global Market

15.43USD
18 Jan 2019
Change (% chg)

$0.21 (+1.38%)
Prev Close
$15.22
Open
$15.29
Day's High
$15.79
Day's Low
$15.00
Volume
59,822
Avg. Vol
112,599
52-wk High
$24.00
52-wk Low
$2.80

Chart for

About

ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates... (more)

Overall

Beta: --
Market Cap(Mil.): $112.31
Shares Outstanding(Mil.): 24.11
Dividend: --
Yield (%): --

Financials

  PRQR.OQ Industry Sector
P/E (TTM): -- 69.71 33.71
EPS (TTM): -2.03 -- --
ROI: -68.51 8.99 14.48
ROE: -75.74 10.13 15.99

ProQR soars as childhood blindness drug succeeds in early trial

Shares of ProQR Therapeutics NV surged 70 percent in premarket trading on Tuesday after an interim analysis of an early-stage trial showed that its experimental treatment for a rare form of childhood blindness improved vision.

05 Sep 2018

UPDATE 1-ProQR soars as childhood blindness drug succeeds in early trial

Sept 5 Shares of ProQR Therapeutics NV surged 70 percent in premarket trading on Tuesday after an interim analysis of an early-stage trial showed that its experimental treatment for a rare form of childhood blindness improved vision.

05 Sep 2018

ProQR drug for rare childhood blindness succeeds in early trial

Sept 5 Dutch drug developer ProQR Therapeutics NV said on Tuesday its interim analysis showed that an early-stage trial of an experimental treatment for a rare form of childhood blindness was successful in improving vision.

05 Sep 2018

Earnings vs. Estimates